Aberrant promoter methylation of multiple genes in oligodendrogliomas and ependymomas.

[1]  M. Alonso,et al.  CpG island methylation status and mutation analysis of the RB1 gene essential promoter region and protein-binding pocket domain in nervous system tumours , 2003, British Journal of Cancer.

[2]  M. Alonso,et al.  Analysis of the NF2 gene in oligodendrogliomas and ependymomas. , 2002, Cancer genetics and cytogenetics.

[3]  H. Ng,et al.  Transcriptional inactivation of TP73 expression in oligodendroglial tumors , 2002, International journal of cancer.

[4]  Y. Yonekawa,et al.  Concurrent Inactivation of RB1 and TP53 Pathways in Anaplastic Oligodendrogliomas , 2001, Journal of neuropathology and experimental neurology.

[5]  M. Wolter,et al.  Oligodendroglial Tumors Frequently Demonstrate Hypermethylation of the CDKN2A (MTS1, p16INK4a), p14ARF, and CDKN2B (MTS2, p15INK4b) Tumor Suppressor Genes , 2001, Journal of neuropathology and experimental neurology.

[6]  A. Jubb,et al.  Methylation and colorectal cancer , 2001, The Journal of pathology.

[7]  F. Wright,et al.  Aberrant promoter methylation of previously unidentified target genes is a common abnormality in medulloblastomas–Implications for tumor biology and potential clinical utility , 2001, Oncogene.

[8]  K. To,et al.  Concurrent Hypermethylation of Multiple Genes Is Associated with Grade of Oligodendroglial Tumors , 2001, Journal of neuropathology and experimental neurology.

[9]  H. Ng,et al.  Identification of novel regions of allelic loss in ependymomas by high-resolution allelotyping with 384 microsatellite markers. , 2001, Journal of neurosurgery.

[10]  M. Alonso,et al.  Mutation analysis of the p73 gene in nonastrocytic brain tumours , 2001, British Journal of Cancer.

[11]  J. Herman,et al.  Promoter hypermethylation of the DNA repair gene O(6)-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis. , 2001, Cancer research.

[12]  J. Herman,et al.  A gene hypermethylation profile of human cancer. , 2001, Cancer research.

[13]  R A Betensky,et al.  Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  W. H. Kim,et al.  CpG island methylation in premalignant stages of gastric carcinoma. , 2001, Cancer research.

[15]  Mitsutoshi Nakamura,et al.  Promoter hypermethylation and homozygous deletion of the p14ARF and p16INK4a genes in oligodendrogliomas , 2001, Acta Neuropathologica.

[16]  A. Chiò,et al.  CDKN2A/p16 inactivation in the prognosis of oligodendrogliomas , 2000, International journal of cancer.

[17]  Scar,et al.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.

[18]  M Noble,et al.  Differential expression of drug resistance genes and chemosensitivity in glial cell lineages correlate with differential response of oligodendrogliomas and astrocytomas to chemotherapy. , 2000, Cancer research.

[19]  D. Louis,et al.  Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. , 2000, Journal of neurosurgery.

[20]  W. Farrell,et al.  Loss of pRb expression in pituitary adenomas is associated with methylation of the RB1 CpG island. , 2000, Cancer research.

[21]  J. Herman,et al.  Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. , 2000, Cancer research.

[22]  B. Scheithauer,et al.  Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J. Rey,et al.  hRAD54 gene and 1p high-resolution deletion-mapping analyses in oligodendrogliomas. , 2000, Cancer genetics and cytogenetics.

[24]  G. Yang,et al.  Mechanisms of inactivation of p14ARF, p15INK4b, and p16INK4a genes in human esophageal squamous cell carcinoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  G. Reifenberger,et al.  Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas. , 1999, The American journal of pathology.

[26]  J. Herman,et al.  Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5' CpG island methylation. , 1999, Cancer research.

[27]  C. Harris,et al.  Mutational analysis of p73 and p53 in human cancer cell lines , 1999, Oncogene.

[28]  N. Ahuja,et al.  Methylation and silencing of the Thrombospondin-1 promoter in human cancer , 1999, Oncogene.

[29]  J. Rey,et al.  NF2 gene mutations and allelic status of 1p, 14q and 22q in sporadic meningiomas , 1999, Oncogene.

[30]  J. Herman,et al.  Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. , 1999, Cancer research.

[31]  J. Herman,et al.  Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. , 1999, Cancer research.

[32]  Peter A. Jones,et al.  Cancer-epigenetics comes of age , 1999, Nature Genetics.

[33]  Peter A. Jones,et al.  The Human ARF Cell Cycle Regulatory Gene Promoter Is a CpG Island Which Can Be Silenced by DNA Methylation and Down-Regulated by Wild-Type p53 , 1998, Molecular and Cellular Biology.

[34]  G. Peters,et al.  The p16INK4a/CDKN2A tumor suppressor and its relatives. , 1998, Biochimica et biophysica acta.

[35]  D. Louis,et al.  Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. , 1998, Journal of the National Cancer Institute.

[36]  Francisco Antequera,et al.  Initiation of DNA replication at CpG islands in mammalian chromosomes , 1998, The EMBO journal.

[37]  L. Matrisian,et al.  Changing views of the role of matrix metalloproteinases in metastasis. , 1997, Journal of the National Cancer Institute.

[38]  C. Sherr.  Cancer Cell Cycles , 1996, Science.

[39]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[40]  D. Roberts,et al.  Regulation of tumor growth and metastasis by thrombospondin‐1 , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[41]  K. Fink,et al.  Infrequency of p53 gene mutations in ependymomas , 1996, Journal of Neuro-Oncology.

[42]  J. Rey,et al.  Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors , 1995, International journal of cancer.

[43]  J. Rey,et al.  Loss of heterozygosity for distal markers on 22q in human gliomas , 1992, International journal of cancer.

[44]  P. Kleihues,et al.  p53 mutations in nonastrocytic human brain tumors. , 1991, Cancer research.

[45]  J. Minna,et al.  Aberrant promoter methylation of multiple genes in non-small cell lung cancers. , 2001, Cancer research.

[46]  J. Herman,et al.  Alterations in DNA methylation: a fundamental aspect of neoplasia. , 1998, Advances in cancer research.

[47]  V. Daniel,et al.  Glutathione S-transferases: gene structure and regulation of expression. , 1993, Critical reviews in biochemistry and molecular biology.

[48]  A. Ouweland,et al.  ©1999 Cancer Research Campaign Article no. bjoc.1999.0822 , 2022 .